T2 Biosystems and Clinicians to Share Clinical Data in Integrated Symposium and Poster Presentations at the European Congress...
April 09 2019 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative medical diagnostic products for critical
unmet needs in healthcare, announced today that the Company will
host an integrated symposium highlighting key clinical data about
the T2Bacteria® and T2Candida® panels at the European Congress of
Clinical Microbiology & Infectious Diseases (ECCMID) in
Amsterdam on Monday, April 15, at 16:00-18:00 Central European Time
(CET). ECCMID will take place April 13-16 at the Amsterdam RAI
Exhibition and Convention Center.
Additionally, seven leading clinicians and users of T2Direct
Diagnostics™ will offer scientific presentations during ECCMID that
will highlight the most recent scientific data on the Company’s
FDA-cleared T2Bacteria and T2Candida Panels. The Company will also
present the first patient case studies with the T2Resistance™
Panel, which recently received FDA Breakthrough designation and is
pending CE mark for commercial availability in Europe. All
presentations will demonstrate the potential for these panels to
significantly improve infectious disease management for patients in
real clinical settings.
“I have seen firsthand how the rapid detection of bacterial and
fungal pathogens with T2Direct Diagnostics can improve patient
outcomes, better manage broad-spectrum antimicrobial usage and
combat antibiotic resistance,” said Neil Clancy, MD, University of
Pittsburgh Medical Center, who is one of the integrated symposium
speakers.
The T2Bacteria and T2Candida Panels are able to identify
sepsis-causing pathogens within 3 to 5 hours directly from whole
blood, instead of days required with blood culture based
diagnostics. This gives clinicians actionable information much
earlier than was previously possible, allowing them to make more
informed treatment plans for escalation or de-escalation of
antimicrobial therapy.
Dr. Clancy continued, “When diagnosing and treating infectious
diseases, time is of the essence. I am proud to be one of the
clinicians here at ECCMID using T2Direct Diagnostics and believe
that we must continue to spread awareness about this rapid
diagnostic technology to improve patient care.”
T2 Biosystems will showcase its latest innovations at Booth
#1.22. The Company will also host an educational event, “Rapid
Diagnostics Direct from Whole Blood: A Solution for Fast and
Appropriate Antimicrobial therapy,” which will be co-chaired by
Prof. Karsten Becker, MD, University Hospital Münster and Prof.
Emmanuel Roilides, MD Aristotle University of Thessaloniki; and it
will include the following presentations:
Integrated Symposium
- “Rapid Diagnostics Direct from Whole Blood: A Solution
for Fast and Appropriate Antimicrobial Therapy,” on
Monday, April 15 from 16:00-18:00 CET in Hall D; presenters
include: • Prof. Michael Bauer, MD, Jena
University (Jena, Germany) • Dr. Cornelius
(Neil) Clancy, University of Pittsburgh Medical Center (Pittsburgh,
PA) • Dr. Giulia De Angelis, Institute of
Microbiology, Università Cattolica del Sacro Cuore, Fondazione
Policlinico Universitario Agostino Gemelli (Rome, Italy)
• Dr. Thomas Walsh, New York Presbyterian
Hospital (New York, NY)
Poster Presentations
- Development of a highly sensitive assay for the
detection of carbapenem-resistance genes from whole blood by T2
magnetic resonance, on Sunday, April 14, from 13:30-14:30
CET (Tom Lowery)
- Real-life diagnostic performance of T2Candida among ICU
patients with risk factors for invasive candidiasis, on
Tuesday, April 16 from 12:30-13:30 CET (Maiken Arendrup)
- The T2Bacteria assay is a sensitive and rapid detector
of bacteraemia that can be initiated in the emergency department
and has potential to favourably influence subsequent
therapy, on Tuesday, April 16 from 12:30-13:30 CET
(Christopher Voigt)
- The T2Bacteria Panel is a rapid detector of bacteraemia
and has potential to guide therapy in patients with haematological
malignancies and haematopoietic stem cell transplantation: a pilot
study of non-culture molecular diagnosis, on Tuesday,
April 16 from 12:30-13:30 CET (Thomas J. Walsh)
- Evaluation of a molecular technology magnetic resonance
for the direct identification of pathogens from blood samples in
paediatric patients with suspected sepsis, on Tuesday,
April 16 from 12:30-13:30 CET (Paola Bernaschi)
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Media Contact: Gina Kent, Vault
Communicationsgkent@vaultcommunications.com +1 610-455-2763
Investor Contact: Zack Kubow, W2O
Groupzkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024